Overview
Inspections by the U.S. Food and Drug Administration (FDA)—as well as by the U.S. Drug Enforcement Administration (DEA) or related federal and state agencies—can have a significant impact on companies that market, or seek to market, drugs, biologics, medical devices, and dietary supplements.
When those inspections go awry, the consequences can be devastating. For example, approval of a new drug application, biologics license application, or medical device marketing authorization may be withheld, and Warning Letters, importation restrictions, seizures, injunctions, or civil monetary or criminal penalties may be issued.
Epstein Becker Green’s Life Sciences team includes attorneys with significant FDA regulatory and compliance experience who are ready to respond to regulatory authority inspections and enforcement matters. We deftly navigate clients through every phase of their regulatory compliance encounters with government agencies—from inspections to the courtroom.
Leading the Response
Compliance with current Good Manufacturing Practices (cGMPs) is critical to ensuring the successful commercialization of new medical therapies in the United States. Approval of a new drug or biologic by the FDA may be conditioned on the agency’s inspection of the applicant’s manufacturing facility. While most are routine audits of the contractor’s plant, equipment, and systems, any adverse finding on the FDA’s inspection report (Form 483) requires a response within 15 days.
If there are adverse findings, our team works closely with a client under this deadline to create a strong response that aims to reduce the likelihood of an FDA enforcement action by convincing the FDA of adequate remediation while legally protecting the client.
Resolving Issues to Avoid Further Government Action
When the FDA wants a company to promptly comply with its regulations, the company may receive a Warning Letter. For clients that receive Warning Letters, we help prepare a response and develop an appropriate corrective action program. We are also experienced at negotiating with the Office of Chief Counsel at the FDA, as well as counterparts in other agencies, and interacting with investigators and compliance officials to prevent and resolve issues.
Providing Civil and Criminal Defense: We Try Cases
When clients find themselves the subject of an investigation or enforcement action by the FDA (via the U.S. Department of Justice (DOJ)) for alleged violations of the Food, Drug, and Cosmetic Act (FDCA), they turn to us. We represent clients in investigations, and, as experienced courtroom lawyers, we vigorously defend them if litigation ensues. We have successfully defended a multitude of clients on DOJ charges relating to FDCA violations in civil, criminal, and administrative cases and represented clients in hundreds of motions before courts and agencies. Clients also come to us to represent them in injunction actions and seizures, and we have litigated or negotiated favorable consent decrees so that our clients can resume their product manufacturing and distribution operations. In addition, we successfully brought legal action against the FDA when it was necessary to protect a client’s interests.
Anticipating Areas of Concern
We also do preventative work. When clients are concerned about possible compliance issues, they often call on us to conduct audits and to assist them in avoiding a problematic regulatory authority inspection. They trust us to understand the FDA’s complex regulatory requirements and expectations, assess regulatory risks, and help them identify and implement best practices going forward. Our combined years of experience in representing clients in FDA inspections and remediation enable us to understand the complexities of cGMPs and how they translate to our client’s organizations.
Read less
Focus Areas
Services
Industries
Experience
- Successfully litigated against the FDA for (i) improper decision of a citizen petition, (ii) improper approval of competitor products, (iii) improper interpretation of the regulation for generic approval, and (iv) arbitrary and capricious actions. We also successfully sued the FDA on a writ of mandamus (which is seldom used against the agency) and declaratory actions.
- Helped a client respond to multisite FDA inspections that resulted in multiple Form FDA-483s, DOJ and DEA involvement, untitled letters, and Warning Letters. We then assisted the client with structuring and executing a company-wide remediation plan to improve compliance with FDA requirements.
- Helped a global biotechnology company respond to multiple FDA inspections that resulted in 483s with dozens of observations. After extensive remediation and communication with the FDA, the agency was satisfied with the company’s remediation efforts and declined to pursue enforcement action against the company.
- Assisted an international biotechnology company in responding to an FDA Warning Letter issued to the company and its contract manufacturer. Observations related to aseptic processing, visual inspection, and supplier qualification and management. No further enforcement action was taken by the FDA.
- Assisted a pharmaceutical company in updating its response to an FDA Form 483. The prior response had led to an immediate classification of the inspection as “Official Action Indicated.” After reviewing the update, the FDA agreed to a prompt follow-up inspection that was classified as “No Action Indication.”
- Served as the principal health regulatory counsel for a multibillion-dollar medical device company during a multi-year quality and regulatory remediation effort. We provided legal advice and guided a multidisciplinary team of scientists, quality experts, regulatory advisors, and lawyers who improved quality and regulatory systems and helped the company avoid significant sanctions.
Contacts
- Member of the Firm
Media
Events
Past Events
Insights
Insights
- BlogsExemptions from the Drug Supply Chain Security Act Enhanced Drug Distribution Security Requirements7 minute read
- Media CoverageMarylana Saadeh Helou Quoted in “FDA Offers Road Map for Remote Trials, but Questions Linger”2 minute read
- Media CoverageKate Heffernan Quoted in “Colleges Get More Leeway to Handle Research Misconduct”2 minute read
- Media CoverageBBA Spotlight Series: Get to Know Emerging Leaders in Boston Law–Marylana Saadeh Helou8 minute read
- Media CoverageChristopher Smith Quoted in “HDA 2024 Traceability Seminar: A Legal Perspective Regarding DSCSA”5 minute read
- PublicationsSumming Up the FDA's Long-Anticipated Draft Guidance on Diversity Action Plans3 minute read
- Media CoverageJames Boiani Quoted in “CMS Takes Baby Steps in New 'Breakthrough' Device Policy”2 minute read
- BlogsPodcast: The Future of Laboratory Testing Just Got a Little Clearer - FDA's Final Rule on LDTs – Diagnosing Health Care2 minute read
- BlogsPodcast: Down Goes Chevron: A 40-Year Precedent Overturned by the Supreme Court – Diagnosing Health Care2 minute read
- Media Coverage
Stuart Gerson Quoted in “FDA’s Lab Developed Test Rule Could Be First Check on Agency’s Power Post-Chevron” ...
3 minute read - BlogsPodcast: If Cannabis Is Reclassified, What Will Happen to the Marketplace? – Diagnosing Health Care2 minute read
- BlogsFDA Wins Mifepristone Case, NLRB Denied Lower Injunctive Relief Standards, and “Trump Too Small” Denied Trademark ...7 minute read
- Media CoverageBradley Merrill Thompson Cited in “AI Regulation: Global Picture Balances Innovation and Insight”3 minute read
- Media CoverageBradley Merrill Thompson Quoted in “Experts Advise Against Prescriptive FDA Policies for Regulating AI”3 minute read
- BlogsNuts or Not Nuts? Second Circuit Declines to Consider Whether KIND’s Use of All-Natural Is Deceptive, Misleading ...5 minute read
- Media CoverageRachel Snyder Good Quoted in “A First in State AI Law”2 minute read
- Blogs
Litigating Nutrition: Class Action Battles Over Dietary Supplements – Speaking of Litigation Video Podcast
41 minute read - Media CoverageJames Boiani Quoted in “Jazz Pharma to Fight FDA in Court Over Rival Sleep Drug Approval”5 minute read
- BlogsFederal Update on Cannabis Scheduling: Are State Legalized Cannabis Dispensaries to Become Pharmacies?7 minute read
- Media Coverage
Kate Heffernan Featured in AHLA’s Speaking of Health Law Podcast, “Trends Related to Research Misconduct” ...
1 minute read - Media CoverageTheodora McCormick Quoted in “‘Vague’ NY Law Looms for the Vitamin Shoppe, Other Supplement Retailers”3 minute read
- Media CoverageTeddy McCormick Quoted in “NPA to Seek Injunction Against NY Law Related to Weight Loss Supplements”4 minute read
- Media CoverageBradley Merrill Thompson Quoted in “Industry Protests FDA Plan to Clear Guidance Backlog by Skipping Comments” ...2 minute read
- Media CoverageBradley Merrill Thompson Quoted in “FDA Warned of Removing Guidance Comment Period in Proposed Plan”2 minute read
- Media CoverageJames Boiani Quoted in “$42M Rat-Infestation Fine Underscores Sanitation Risks Facing Warehouses”3 minute read
- Media CoverageBradley Merrill Thompson Discusses “Problematic Guidance Patterns Remain at FDA”2 minute read
- Media CoverageMegan Robertson Quoted in “FDA and CMS Leaders Unite Over Proposed Lab Test Rule”2 minute read
- Media CoverageBradley Merrill Thompson Discusses Clinical Decision Support, Medical Devices, and AI in Yale Video1 minute read
- Media CoverageJames Boiani Quoted in “Clinical Lab Consolidation Continues in 2023 While Key Policy Questions Go Unresolved” ...2 minute read
- Media CoverageJames Boiani Quoted in “FDA Braces for High Court, Final Rule Moves in Election Year”3 minute read
- Publications9th Circ. Scienter Ruling May Strengthen FDA's Leverage1 minute read
- Media CoverageJames Boiani Quoted in “FDA Moving Quickly on LDT Rulemaking as 2024 Elections, 2027 User Fee Renewal Loom” ...2 minute read
- Media CoverageJames Boiani Quoted in “Proposed FDA Rule Sets Stage for New Round of Battle Over LDT Regulation”5 minute read
- BlogsFull Steam Ahead: FDA Releases Proposed LDT Rule in Advance of Looming Government Shutdown4 minute read
- Media CoverageJames Boiani Quoted in “FDA Wants Oversight of Lab-Developed Tests”2 minute read
- PublicationsA Topic-Based Analysis of FDA Responses to FOIA Requests1 minute read
- Media CoverageJames Boiani Quoted in “FDA Moves to Modernize Medical Devices Premarket Program”3 minute read
- BlogsFDA Oversight of AI Software Developed by Health Care Providers23 minute read
- PublicationsDietary Supplement Makers Face "Misbranding" Minefield, Need FDA Guidance7 minute read
- PublicationsWhat’s on the Agenda? Laboratory Developed Tests Added to the Unified Regulatory Agenda Signals FDA Movement Toward New ...26 minute read
- Firm Announcements
Jessika Tuazon Named to the 2023 Southern California Rising Stars List
6 minute read - PublicationsBy Leaving "Therapeutic Alternatives" Undefined, CMS Tilts the Playing Field of Drug Price Negotiations3 minute read
- Media CoverageBradley Merrill Thompson Quoted in “Ready or Not, AI Chatbots Are Coming to Hospitals”3 minute read
- Media CoverageBradley Merrill Thompson Quoted in “FDA Draft Guidance Allows AI/ML Devices to Evolve Without Requiring New ...5 minute read
- Media CoverageBradley Merrill Thompson Quoted in “FDA Draft Guidance for AI Change Control Shifts Workload to Initial Premarket ...1 minute read
- Media CoverageJames Boiani Quoted in “The Hazy Future of the VALID Act”2 minute read
- PublicationsBradley Merrill Thompson Quoted in “FDA’s Human Factors Draft Draws Fire for Introduction of ‘Critical Task’ ...2 minute read
- Media CoverageBradley Merrill Thompson Quoted in “FDA Outlines Plan for Digital Health Technologies for Clinical Trials”4 minute read
- Media CoverageBradley Merrill Thompson Quoted in “The FDA Plans to Regulate Far More AI Tools as Devices. The Industry Won’t Go Down ...2 minute read
- Media CoverageBradley Merrill Thompson Discusses FDA Regulatory Hurdles for Breakthrough Devices2 minute read